Skip to main content
Equibles

Ash Verma

Analyst

UBS

Equibles does not estimate personal net worth.

About Ash Verma

Ash Verma is recorded as Analyst at UBS. Ash Verma has spoken on 23 earnings calls and 1 other investor event across 12 companies, most recently for Alvotech on August 20, 2026. Those appearances were for Teva Pharmaceutical Industries Ltd (TEVA), Viatris Inc (VTRS), Alvotech (ALVO), Royalty Pharma plc (RPRX), Acadia Pharmaceuticals Inc (ACAD) and 7 other companies. The companies whose calls Ash Verma spoke on are classified in the Healthcare sector.

Ash Verma on recent calls

“I wanted to ask about first just on this DEA that you received from the FDA for these U.S. submissions.”
Analyst — UBS, Q2 2026 Earnings Call ·
“Maybe just on China, so great to see solid operational growth here that you've seen in the first two quarters. I know you've noted e-commerce has been a big source of growth.”
Analyst — UBS, Viatris Inc Q2 FY2026 Earnings Call ·
“So yeah, I have kind of like a similar question, just a prescription with the dispense. So I know when you provided the first quarter update, you mentioned about the April prescription.”
Analyst — UBS, Cytokinetics Q2 2026 Earnings Conference Call ·
“Maybe just the first one, just going back to slide 15, the investor capital work, Can you remind us what type of IRR are you able to drive with the development state assets versus the approved?”
Analyst — UBS, Royalty Pharma Q2 2026 Financial Results Call ·

Affiliation history

  • UBS

    Analyst

    Source not stated

    Current

Company network

Recent activity

Show 12 earlier activities